Addex Therapeutics Ltd
ADXN
$9.44
$0.525.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | 53.60% | 57.44% | 40.30% | 578.56% |
| Total Depreciation and Amortization | -- | -29.41% | 721.21% | 1,775.76% | 3,666.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 164.55% | 11.95% | 88.26% | -2,021.56% |
| Change in Net Operating Assets | -- | -103.01% | -72.07% | 189.01% | -201.66% |
| Cash from Operations | -- | 73.46% | 96.19% | 81.93% | 0.62% |
| Capital Expenditure | -- | -- | 100.00% | -87.50% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -1,192.86% | -750.00% | 184,417.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 97.30% | 97.40% | 96.95% | 88.72% |
| Issuance of Common Stock | -- | -99.87% | -90.42% | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | -50.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 10,050.00% | 44.44% | 99.48% | -100.94% |
| Cash from Financing | -- | -42.08% | 96.97% | 99.72% | -101.27% |
| Foreign Exchange rate Adjustments | -- | -115.43% | 116.50% | -228.38% | 101.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 77.56% | 99.15% | 81.45% | 36.40% |